Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
Authors:
Open Access
- 1 July 2016
- journal article
- review article
- Published by Elsevier in Biologicals
- Vol. 44 (4) , 257-266
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Clinical experience with Zarzio® in Europe: what have we learned?Supportive Care in Cancer, 2013
- Pharmacovigilance and biosimilars: considerations, needs and challengesExpert Opinion on Biological Therapy, 2013
- Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR StudyAnnals of the Rheumatic Diseases, 2012
- The safety of switching between therapeutic proteinsExpert Opinion on Biological Therapy, 2012
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factorAdvances in Therapy, 2011
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanerceptAnnals of the Rheumatic Diseases, 2011
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseGastroenterology, 2003